Radiopharm Theranostics Ltd (ASX:RAD) CEO Riccardo Canevari tells Proactive the Australian oncology company has debuted on the ASX, targeting a $50 million raise, bringing its market cap to $152 million. Canevari says it will use its radiopharmaceutical therapeutics to selectively kill cancer cells in patients, an alternative technology to that of chemotherapy, immuno-oncology, and cell and gene therapy.
Radiopharm Theranostics makes its debut on the ASX as it develops its cancer killing technology
